CKPT250117C7500
- 0.10
- -0.04-28.57%
Checkpoint Therapeutics Newsroom
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Raises Target Price to $7
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Checkpoint Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Checkpoint Therapeutics (CKPT) and Roche Holding AG (OtherRHHVF)
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Checkpoint Therapeutics Analyst Ratings
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Optimistic Buy Rating for Checkpoint Therapeutics Driven by Strong Financial Position and Strategic Collaborations
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Announces Target Price $4
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Cuts Target Price to $20
Checkpoint Therapeutics Analyst Ratings
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating
Lake Street Remains a Buy on Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Lake Street Sticks to Its Buy Rating for Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
Checkpoint Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target